Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy.

ANV419 - Anaveon

Herceptin (trastuzumab) - Roche

Proleukin (aldesleukin) - Merck (MSD), Novartis, Iovance Biotherap

http://www.ncbi.nlm.nih.gov/pubmed/39041287

Andreas Katopodis; Barbara Brannetti; Catherine Régnier; Christoph Huber; Jean-Michel Rondeau; Kirsten Richter; Laetitia Petersen; Nicole Egli; Patrizia Murer; Simone Popp

Jul 23, 2024